Concept of Robotic Gamma Knife Microradiosurgery and Results of Its Clinical Application in Benign Skull Base Tumors

Author(s):  
Motohiro Hayashi ◽  
Mikhail F. Chernov ◽  
Noriko Tamura ◽  
Masahiro Izawa ◽  
Yoshihiro Muragaki ◽  
...  
2002 ◽  
Vol 40 (2) ◽  
pp. 99-103 ◽  
Author(s):  
Asle Hirth ◽  
Paal-Henning Pedersen ◽  
Roald Baardsen ◽  
John Ludvig Larsen ◽  
B�rd K. Krossnes ◽  
...  

2002 ◽  
Vol 97 ◽  
pp. 674-676 ◽  
Author(s):  
Paul C. Francel ◽  
Sumon Bhattacharjee ◽  
Paul Tompkins

Object. The purpose of this study was to evaluate descriptive data obtained in patients who had received multimodality treatment with resection and gamma knife radiosurgery (GKS) for skull base tumors. Retrospective data were collected from 71 patients with skull base tumors who were treated from November 1996 to December 2000, all of whom underwent follow-up evaluation at 1 year or more. Methods. Data were collected from hospital charts and office records, including patient age, tumor type and location, number of tumors, maximum radiation dose, estimated radiation dose to the periphery, tumor volume, and percentage of patients with tumors smaller or the same size at follow-up evaluation. Conclusions. Of the 71 patients with 1 year or more of follow up, 93% had tumor either the same size or smaller and 34% of these patients had a smaller tumor size. It is concluded that: 1) GKS with multimodality treatment is effective for control of skull base tumors; 2) the radiosurgical team should consider the benefits of GKS for treatment of any skull base tumor to afford optimum patient management; and 3) neurosurgeons involved with the management of skull base tumors should either be trained and proficient in GKS or work closely with a colleague trained in the technique. This will ensure proper consideration of both options, resulting in overall improved patient treatment.


Radiosurgery ◽  
2010 ◽  
pp. 227-236 ◽  
Author(s):  
Motohiro Hayashi ◽  
Noriko Tamura ◽  
Kotaro Nakaya ◽  
Taku Ochiai ◽  
Mikhail Chernov ◽  
...  

2019 ◽  
Vol 130 (3) ◽  
pp. 812-821 ◽  
Author(s):  
Jack Phan ◽  
Courtney Pollard ◽  
Paul D. Brown ◽  
Nandita Guha-Thakurta ◽  
Adam S. Garden ◽  
...  

OBJECTIVEThe objective of this study was to assess outcomes after Gamma Knife radiosurgery (GKRS) re-irradiation for palliation of patients with trigeminal pain secondary to recurrent malignant skull base tumors.METHODSFrom 2009 to 2016, 26 patients who had previously undergone radiation treatment to the head and neck received GKRS for palliation of trigeminal neuropathic pain secondary to recurrence of malignant skull base tumors. Twenty-two patients received single-fraction GKRS to a median dose of 17 Gy (range 15–20 Gy) prescribed to the 50% isodose line (range 43%–55%). Four patients received fractionated Gamma Knife Extend therapy to a median dose of 24 Gy in 3 fractions (range 21–27 Gy) prescribed to the 50% isodose line (range 45%–50%). Those with at least a 3-month follow-up were assessed for symptom palliation. Self-reported pain was evaluated by the numeric rating scale (NRS) and MD Anderson Symptom Inventory–Head and Neck (MDASI-HN) pain score. Frequency of as-needed (PRN) analgesic use and opioid requirement were also assessed. Baseline opioid dose was reported as a fentanyl-equivalent dose (FED) and PRN for breakthrough pain use as oral morphine-equivalent dose (OMED). The chi-square and Student t-tests were used to determine differences before and after GKRS.RESULTSSeven patients (29%) were excluded due to local disease progression. Two experienced progression at the first follow-up, and 5 had local recurrence from disease outside the GKRS volume. Nineteen patients were assessed for symptom palliation with a median follow-up duration of 10.4 months (range 3.0–34.4 months). At 3 months after GKRS, the NRS scores (n = 19) decreased from 4.65 ± 3.45 to 1.47 ± 2.11 (p < 0.001); MDASI-HN pain scores (n = 13) decreased from 5.02 ± 1.68 to 2.02 ± 1.54 (p < 0.01); scheduled FED (n = 19) decreased from 62.4 ± 102.1 to 27.9 ± 45.5 mcg/hr (p < 0.01); PRN OMED (n = 19) decreased from 43.9 ± 77.5 to 10.9 ± 20.8 mg/day (p = 0.02); and frequency of any PRN analgesic use (n = 19) decreased from 0.49 ± 0.55 to 1.33 ± 0.90 per day (p = 0.08). At 6 months after GKRS, 9 (56%) of 16 patients reported being pain free (NRS score 0), with 6 (67%) of the 9 being both pain free and not requiring analgesic medications. One patient treated early in our experience developed a temporary increase in trigeminal pain 3–4 days after GKRS requiring hospitalization. All subsequently treated patients were given a single dose of intravenous steroids immediately after GKRS followed by a 2–3-week oral steroid taper. No further cases of increased or new pain after treatment were observed after this intervention.CONCLUSIONSGKRS for palliation of trigeminal pain secondary to recurrent malignant skull base tumors demonstrated a significant decrease in patient-reported pain and opioid requirement. Additional patients and a longer follow-up duration are needed to assess durability of symptom relief and local control.


Sign in / Sign up

Export Citation Format

Share Document